KIT and gastrointestinal stromal tumor: Another phase II trial titled “Ponatinib in patients with metastatic and/or unresectable GISTs following failure or intolerance to prior therapy with imatinib”, (ClinicalTrials.gov Id: NCT03171389) plans to define the efficacy and safety of ponatinib in GIST patients resistant to imatinib, assessing, by liquid biopsies, the presence of circulating DNA from secondary mutations in KIT exon 13.